Lifesci Capital Issues Optimistic Outlook for SLNO Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Research analysts at Lifesci Capital boosted their Q4 2025 earnings per share estimates for Soleno Therapeutics in a research report issued on Monday, January 12th. Lifesci Capital analyst K. Dellorusso now anticipates that the company will earn $0.59 per share for the quarter, up from their prior estimate of $0.46. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q1 2026 earnings at $0.58 EPS, Q2 2026 earnings at $0.71 EPS, Q3 2026 earnings at $0.74 EPS, Q4 2026 earnings at $0.91 EPS and FY2026 earnings at $3.42 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.08 by $0.39. The company had revenue of $66.02 million for the quarter, compared to analyst estimates of $47.46 million.

Several other analysts have also recently weighed in on SLNO. Wall Street Zen raised shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Zacks Research upgraded shares of Soleno Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. The Goldman Sachs Group set a $125.00 target price on shares of Soleno Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $106.00 price target (down from $123.00) on shares of Soleno Therapeutics in a report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $109.23.

Soleno Therapeutics Price Performance

SLNO stock opened at $42.48 on Thursday. The business’s 50-day moving average is $47.58 and its two-hundred day moving average is $62.74. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88. The firm has a market capitalization of $2.28 billion, a P/E ratio of -23.09 and a beta of -3.12. Soleno Therapeutics has a 1 year low of $39.43 and a 1 year high of $90.32.

Institutional Trading of Soleno Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Soleno Therapeutics by 1.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after purchasing an additional 189 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Soleno Therapeutics in the second quarter valued at approximately $25,000. Avanza Fonder AB grew its position in shares of Soleno Therapeutics by 11.2% during the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock worth $148,000 after acquiring an additional 323 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Soleno Therapeutics by 11.9% in the 3rd quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock valued at $216,000 after acquiring an additional 340 shares during the period. Finally, New York State Common Retirement Fund raised its position in Soleno Therapeutics by 2.4% in the 3rd quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock valued at $1,055,000 after purchasing an additional 360 shares during the last quarter. 97.42% of the stock is owned by hedge funds and other institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.